Evonik Launches Ready-to-Use Powder Premix to Improve Processing, Appearance & Swallowability of Oral Drug Products With an Immediate-Release Profile
Evonik recently launched a new ready-to-use powder premix blend of its EUDRAGIT functional polymers used for oral products with an immediate-release profile.
EUDRAGIT IR ReadyMix White is fast and easy-to-process, with a high-gloss coating delivering an elegant optical appearance and superior swallowability outcomes. As a fully formulated, powder premix blend of EUDRAGIT E PO that meets the requirements of all major pharmacopoeias, it is readily available for shipment as a standard product.
“EUDRAGIT has been the world’s preferred brand of functional polymers used with oral drug products for more than 60 years,” said Matthias Wiehn, Global Product Manager of Evonik’s Oral Drug Delivery Solutions business. “With the launch of EUDRAGIT IR ReadyMix White, pharmaceutical companies now have an immediate and attractive choice to optimize the processability, appearance, taste, and swallowability of drug products with an immediate-release profile.”
EUDRAGIT IR ReadyMix White is suitable for use with tablets and a range of other solid oral dosage forms. Due to its high solid content and low processing temperature, the premix can be processed in around half the time as HPMC or PVA-based ready-to-use alternatives, which reduces cost and improves batch productivity. In addition to having a visually elegant high-gloss coating, its non-sticky behavior and intactness while inside the mouth can help to enhance swallowability.
EUDRAGIT IR ReadyMix White is the second ready-to-use premix blend developed by Evonik for use with oral drug products with an immediate-release profile. Evonik’s first ready-to-use premix product known as EUDRAGIT E PO ReadyMix shares many of the same processing and rapid dissolution advantages as EUDRAGIT IR ReadyMix White, but is custom tailored for use with oral drug products requiring superior color matching, moisture protection, or taste-masking outcomes.
EUDRAGIT is the industry’s preferred portfolio of functional polymers for use with oral drug products that have an immediate-, delayed-, or sustained-release profile. The breadth, versatility, and history of EUDRAGIT, combined with Evonik’s range of drug delivery technologies, formulation, and cGMP manufacturing services, provides pharmaceutical companies with unrivalled safety and functional reliability for their oral solid dosage forms.
Evonik’s Health Care business line, which is part of the Nutrition and Care division of Evonik, is one of the world’s leading CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest pharmaceutical suppliers of generic APIs, amino acids, and cell culture ingredients, and a top 3 global CMO for APIs and intermediates.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around €2.9 billion in 2019 with about 5,300 employees. It is part of Evonik Operations GmbH.
Total Page Views: 530